These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 24753251

  • 1. Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia.
    Waight JD, Banik D, Griffiths EA, Nemeth MJ, Abrams SI.
    J Biol Chem; 2014 May 30; 289(22):15642-52. PubMed ID: 24753251
    [Abstract] [Full Text] [Related]

  • 2. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C.
    Blood; 2005 Apr 15; 105(8):3303-11. PubMed ID: 15626746
    [Abstract] [Full Text] [Related]

  • 3. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA, Jusoh SA, Yong AC, Asan JM, Hassan R, Johan MF.
    Asian Pac J Cancer Prev; 2014 Apr 15; 15(11):4555-61. PubMed ID: 24969884
    [Abstract] [Full Text] [Related]

  • 4. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
    Grimaudo S, Meli M, Di Cristina A, Ferro A, Pipitone MR, Romagnoli R, Simoni D, Dieli F, Tolomeo M.
    Anticancer Drugs; 2013 Apr 15; 24(4):384-93. PubMed ID: 23370613
    [Abstract] [Full Text] [Related]

  • 5. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
    Niu CC, Zhao C, Yang ZD, Zhang XL, Wu WR, Pan J, Zhao C, Li ZQ, Ding W, Yang Z, Si WK.
    Int J Mol Med; 2013 Feb 15; 31(2):453-8. PubMed ID: 23233089
    [Abstract] [Full Text] [Related]

  • 6. Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells.
    Huang Q, Yang Y, Li X, Huang S.
    Tumour Biol; 2011 Dec 15; 32(6):1191-7. PubMed ID: 21892628
    [Abstract] [Full Text] [Related]

  • 7. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.
    Yuan H, Wang Z, Li L, Zhang H, Modi H, Horne D, Bhatia R, Chen W.
    Blood; 2012 Feb 23; 119(8):1904-14. PubMed ID: 22207735
    [Abstract] [Full Text] [Related]

  • 8. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML).
    Scherr M, Chaturvedi A, Battmer K, Dallmann I, Schultheis B, Ganser A, Eder M.
    Blood; 2006 Apr 15; 107(8):3279-87. PubMed ID: 16278304
    [Abstract] [Full Text] [Related]

  • 9. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 10. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.
    Hantschel O, Warsch W, Eckelhart E, Kaupe I, Grebien F, Wagner KU, Superti-Furga G, Sexl V.
    Nat Chem Biol; 2012 Jan 29; 8(3):285-93. PubMed ID: 22286129
    [Abstract] [Full Text] [Related]

  • 11. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.
    Dong B, Liang Z, Chen Z, Li B, Zheng L, Yang J, Zhou H, Qu L.
    Sci China Life Sci; 2018 Sep 29; 61(9):999-1009. PubMed ID: 30054832
    [Abstract] [Full Text] [Related]

  • 12. Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling.
    Nam S, Scuto A, Yang F, Chen W, Park S, Yoo HS, Konig H, Bhatia R, Cheng X, Merz KH, Eisenbrand G, Jove R.
    Mol Oncol; 2012 Jun 29; 6(3):276-83. PubMed ID: 22387217
    [Abstract] [Full Text] [Related]

  • 13. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
    Shi X, Chen X, Li X, Lan X, Zhao C, Liu S, Huang H, Liu N, Liao S, Song W, Zhou P, Wang S, Xu L, Wang X, Dou QP, Liu J.
    Clin Cancer Res; 2014 Jan 01; 20(1):151-63. PubMed ID: 24334603
    [Abstract] [Full Text] [Related]

  • 14. Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.
    Okabe S, Tauchi T, Katagiri S, Tanaka Y, Ohyashiki K.
    J Hematol Oncol; 2014 Apr 28; 7():37. PubMed ID: 24775308
    [Abstract] [Full Text] [Related]

  • 15. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M, Nguyen TK, Dent P, Grant S.
    Mol Pharmacol; 2007 Sep 28; 72(3):788-95. PubMed ID: 17595328
    [Abstract] [Full Text] [Related]

  • 16. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.
    Yamada O, Ozaki K, Furukawa T, Machida M, Wang YH, Motoji T, Mitsuishi T, Akiyama M, Yamada H, Kawauchi K, Matsuoka R.
    Cell Signal; 2011 Jul 28; 23(7):1119-27. PubMed ID: 21356308
    [Abstract] [Full Text] [Related]

  • 17. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.
    Cancer Res; 2005 Oct 01; 65(19):8912-9. PubMed ID: 16204063
    [Abstract] [Full Text] [Related]

  • 18. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
    Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, Sillaber C, Esterbauer H, Valent P.
    Cancer Res; 2005 Oct 15; 65(20):9436-44. PubMed ID: 16230407
    [Abstract] [Full Text] [Related]

  • 19. Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells.
    Wang XY, Sun GB, Wang YJ, Yan F.
    Biol Pharm Bull; 2020 Oct 15; 43(10):1526-1533. PubMed ID: 32999163
    [Abstract] [Full Text] [Related]

  • 20. Bcr-abl regulates Stat5 through Shp2, the interferon consensus sequence binding protein (Icsbp/Irf8), growth arrest specific 2 (Gas2) and calpain.
    Hjort EE, Huang W, Hu L, Eklund EA.
    Oncotarget; 2016 Nov 22; 7(47):77635-77650. PubMed ID: 27769062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.